Immunocore Holdings Ltd (IMCR)vsMerck & Company Inc (MRK)
IMCR
Immunocore Holdings Ltd
$27.91
-0.04%
HEALTHCARE · Cap: $1.42B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 16152% more annual revenue ($65.01B vs $400.02M). MRK leads profitability with a 28.1% profit margin vs -8.9%. MRK earns a higher WallStSmart Score of 59/100 (C).
IMCR
Hold43
out of 100
Grade: D
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+2.5%
Fair Value
$33.76
Current Price
$27.91
$5.85 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 822.0% YoY
Revenue surging 24.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -9.6% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCR
The strongest argument for IMCR centers on EPS Growth, Revenue Growth. Revenue growth of 24.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : IMCR
The primary concerns for IMCR are Market Cap, Operating Margin, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IMCR profiles as a growth stock while MRK is a value play — different risk/reward profiles.
IMCR carries more volatility with a beta of 0.83 — expect wider price swings.
IMCR is growing revenue faster at 24.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 43/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immunocore Holdings Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?